
doi: 10.1111/cup.13892
pmid: 33089535
AbstractTrichoblastic carcinosarcomas are rare, adnexal‐type cutaneous carcinosarcomas that are thought to be related histogenetically to trichoblastomas, yet in which both the epithelial and stromal components show features of malignancy. Ten cases have been described in the literature thus far, with a predilection for the head and neck of older males. We present a case of cutaneous carcinosarcoma in sun‐damaged skin of a 34‐year‐old woman showing features of a trichoblastic carcinosarcoma, with histopathologic analysis along with targeted next‐generation sequencing of 50 cancer‐associated genes. Two pathogenic variants in TP53 were identified, p.(R158C), p.(R273P), along with a likely pathogenic variant CDKN2A, p.(R58*). In particular, it is noted that the CDKN2A p.(R58*) missense mutation has been described in two previous cases of cutaneous carcinosarcomas, including a case of trichoblastic carcinosarcoma.
Adult, Skin Neoplasms, Carcinosarcoma, Mutation, Missense, Humans, Female, Tumor Suppressor Protein p53, Cyclin-Dependent Kinase Inhibitor p16
Adult, Skin Neoplasms, Carcinosarcoma, Mutation, Missense, Humans, Female, Tumor Suppressor Protein p53, Cyclin-Dependent Kinase Inhibitor p16
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 9 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
